Inquis Medical has announced the closing of a US$75 million series C financing round.
The company have stated in a recent press release that the financing follows a transformative 2025 during which Inquis Medical successfully transitioned into a commercial-stage organisation. Key achievements include expanded regulatory clearance for pulmonary embolism (PE) and publication of pivotal trial data in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI). The published data demonstrated significant thrombus removal while minimising blood loss through integrated autologous blood reinfusion in 130 patients with intermediate-risk PE with no device-related adverse events.
“The successful closing of our series C financing marks a pivotal inflection point for Inquis Medical as we scale our footprint in the VTE [venous thromboembolism] market,” said Vahid Saadat, co-founder and co-chief executive officer (CEO) of Inquis Medical. “This partnership with a strategic investor provides the capital necessary to execute our long-term vision of redefining the standard of care in VTE through the convergence of clinical excellence and technological innovation.”
This latest round builds upon the momentum established by a US$40 million series B financing, led by Marshall Wace, completed in August 2024.
“This capital infusion is a strong endorsement of our commercial trajectory and the clinical progress our team has achieved,” said Mojgan Saadat, co-founder and co-CEO of Inquis Medical. “With this investment, we are well positioned to scale our market presence and advance our innovation roadmap, ensuring physicians have access to advanced tools to improve outcomes in VTE care.”
